A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Alectinib
DRUG: Atezolizumab
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Gemcitabine
DRUG: Entrectinib
DRUG: Cobimetinib
DRUG: Vemurafenib
DRUG: Bevacizumab
DRUG: Divarasib
DRUG: Docetaxel

Sponsor

Hoffmann-La Roche